Medical Groups/Interested Parties: Multi-product Tender consultation (text extract)

This is the text extract for Medical Groups/Interested Parties: Multi-product Tender consultation, browse documents here.

21 August 2009

2009/10 Multi-product Tender

PHARMAC is seeking feedback from Medical Groups, DHB Hospital Pharmacies and other Interested Parties on: • • A proposal to tender certain pharmaceuticals for sole supply; and The draft process and terms and conditions for the Invitation to Tender 2009/10.

PHARMAC welcomes all feedback.

ALL RESPONSES ARE DUE BY 5PM, FRIDAY 2 OCTOBER 2009

Feedback should be provided by submitting an email, fax or letter to: Yvonne Chen Tender Analyst PHARMAC PO Box 10-254 Wellington 6143 Email: yvonne.chen@pharmac.govt.nz Fax: (04) 460 4995 DDI: (04) 916 7556

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposed 2009/10 multi-product tender In accordance with PHARMAC’s objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided) PHARMAC is consulting on a proposal to tender, for Sole Subsidised Supply and/or Hospital Supply Status, certain pharmaceuticals. Attached to this letter (as Schedule One) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a ‘C’ and/or ‘H’ next to it to indicate whether it is proposed to be tendered for community and/or hospital supply. In general, the proposed Tender process would be similar to the 2008/09 Tender. A copy of the draft 2009/10 Invitation to Tender is available on our website: www.pharmac.govt.nz, or by contacting PHARMAC. We are seeking feedback on the approach outlined in the following pages, in particular on: • • The proposed process; The proposed timetable;

A301042 - qA15909

• •

The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and For hospital pharmaceuticals, your views on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event you consider a 1% Discretionary Variance Limit to be clinically unacceptable.

Background Since 1997 PHARMAC has been using the strategy of tendering for the sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. It is proposed that, as in the past, the community Tender and hospital Tender processes are run in unison, however the pharmaceutical list for community and hospital pharmacies may be different. Key Aspects of Awarding a Tender for Community Pharmaceuticals: • For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2013 for all Tenders awarded from the 2009/10 Invitation to Tender. The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer’s surcharge (that is the additional patient charge above that of the patient co-payment), would become fully subsidised if a Tender was awarded. No other brand of the pharmaceutical could be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Tender period. Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a subsidy.

•

• •

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals: • For DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2013 for all Tenders awarded from the 2009/10 Invitation to Tender. No other brand of the pharmaceutical would be listed (or purchased) in Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.

•

Tender Timelines The Tender process is run annually. This year we are proposing to bring the tender timelines forward by one month; the proposed timelines for the 2009/10 Tender are as follows: Date

August/September 2009 2 October 2009 (5 pm) October 2009 A301042 - qA15909

Event

Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for all consultation to be received. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. 2

Date

October/November 2009 Late November 2009 Late January 2010 From February 2010 30 June 2013

Event

Consultation and Board decisions on Alternative Commercial Proposals to tendering from pharmaceutical suppliers. Issuing of the 2009/10 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2009/10 Tender. Terms after the End Date may apply.

Depending on the feedback received from consultation this year, PHARMAC proposes to bring forward the tender timelines by a further month in the 2010/11 Tender, as this may help to alleviate a number of stock management issues for pharmaceutical suppliers that currently exist during the transition period of a brand change.

Reference Pricing in the Community Reference pricing, in the community market, is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list in Schedule One contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios in the community market including: 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup; and/or 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider and provide feedback on any clinical issues associated with such scenarios.

Contractual obligations for suppliers A copy of the draft terms and conditions which would form the terms of the contract with successful suppliers in the 2009/10 Tender is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50.

Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 21 December 2007 (2007/08 Tender) and the Invitation to Tender dated 23 December 2008 (2008/09 Tender) prior to issuing the 2009/10 Invitation to Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in November 2009. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule One.

A301042 - qA15909 3

PHARMAC is currently seeking comments from suppliers about keeping any unresolved Tender Bid(s) open for acceptance.

Distribution of Consultation Documents Please note that this consultation letter has been widely distributed, however should you consider that a particular person, group or agency should receive this letter and/or future Tender documents please feel free to contact PHARMAC (note, all Tender documents and consultations are also available from our website). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

A301042 - qA15909

Schedule One: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule The pharmaceuticals have been listed in therapeutic groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one.

Therapeutic Group Alimentary Tract and Metabolism Blood and Blood Forming Organs Cardiovascular System Dermatologicals Extemporaneously Compounded Preparations Genito-Urinary System Hormone Preparations – Systemic excluding contraceptives Infections – Agents for Systemic Use Musculoskeletal System Nervous System Oncology and Immunosuppressants Respiratory System and Allergies Sensory Organ Various Page Numbers 7–9 9 – 10 10 – 11 11 – 13 13 13 13 – 14 14 – 15 15 – 16 16 – 22 22 – 26 26 26 26

Information provided for each pharmaceutical For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information: • • the current ex-manufacturer subsidy per unit of measure as at 1 August 2009; number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2009. We note that these figures have not yet been finalised; however finalised data would be captured in the final Invitation to Tender; estimated annual community market value at current subsidies; and comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

• •

The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June 2009. These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals. We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2009 by the relevant listed unit subsidy as at 1 August 2009.

A301042 - qA15909

Explanation of terms, symbols and abbreviations Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed. The following table explains the symbols used in the draft pharmaceutical list:

Symbol Underline C H PCT + * Explanation Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2010 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date. To be tendered for Sole Subsidised Supply (community pharmaceuticals). To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals). A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project. PHARMAC has been advised of the existence of a process patent. There is no fully funded product available for this line item (in relation to community supply).

A301042 - qA15909

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Units Cost Unit Subsidy DV Limit Comments

Alimentary Tract and Metabolism

Ascorbic Acid Eye drops 10% Inj 500 mg per 5 ml Tab 50 mg Tab 100 mg Tab 250 mg 1,329,567 $45,870 $0.0345 H H C H C H C H 1% 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Bisacodyl Tab 5 mg Cholecalciferol Tab 1.25 mg (50,000 iu) Esomeprazole Inj 40 mg Tab 20 mg Tab 40 mg C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

1,551,489

$39,485

$0.0255

C H

1,176,907

$1,015,082

$0.8625

C H

Famotidine Tab 20 mg Tab 40 mg Ferrous Salts Oral liq Tab (short-acting) 3,817,372 $78,638 $0.0206 C H C H 1% 1%

Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required

709,966 621,078

$23,003 $28,197

$0.0324 $0.0454

C H C H

1% 1%

Tab (long-acting)

C H

Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g 2,353,042 $498,061 $0.2117 C H 1%

All corticosteroids ointments in the antihaemmorrhoidals group are considered as one Tender Item All corticosteroids suppositories in the antihaemmorrhoidals group are considered as one Tender Item

Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg

730,228

$161,867

$0.2217

C H

Glimepiride Tab 1 mg Tab 2 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Glimepiride Tab 3 mg Tab 4 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

Glycerol Suppos 3 g or less Suppos greater than 3 g Hydrocortisone with Cinchocaine Oint 5 mg with cinchocaine hydrochloride 5 mg per g C H 1%

Not currently listed in the Pharmaceutical Schedule. All corticosteroids ointments in the antihaemmorrhoidals group are considered as one Tender Item Not currently listed in the Pharmaceutical Schedule. All corticosteroids suppositories in the antihaemmorrhoidals group are considered as one Tender Item

56,472 263,122

$14,683 $65,781

$0.2600 $0.2500

C H C H

1% 1%

Suppos 5 mg with cinchocaine hydrochloride 5 mg per g

C H

Hydrocortisone with Lignocaine, Aluminium and Zinc Oint 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18% C H 1%

Suppos 0.25% with lignocaine hydrochloride 5% aluminium subacet 3.5% and zinc oxide 18%

C H

Lactulose Oral liq 10 g per 15 ml Loperamide Hydrochloride Tab 2 mg 6,069,760 $174,506 $0.0288 C

Capsule form would be considered

182,005,412

$1,210,336

$0.0067

C H

Mesalazine Tab 400 mg Miconazole Oral gel 20 mg per g Nizatidine Cap 150 mg Cap 300 mg C C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

2,197,126

$1,087,577

$0.4950

C H

660,769

$143,717

$0.2175

C H

Pantoprazole Inj 40 mg Tab 20 mg 4,351,274 $348,102 $8.7500 $0.0800 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Pantoprazole Tab 40 mg Pyridoxine Hydrochloride Tab 25 mg Rabeprazole Tab 10 mg Tab 20 mg $0.0000 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

7,307,110

$876,853

$0.1200

C H

643,577

$21,882

$0.0340

C H

Sodium Citrate with Sodium Lauryl Sulphoacetate Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Vitamin B Complex (BPC, strong) Tab Vitamins (BPC cap strength) Tab 24,790,242 $366,896 $0.0148 C 2,369,926 $57,352 $0.0242 C 339,630 $206,597 $0.6083 C H 1%

Blood and Blood Forming Organs

Aspirin Tab 100 mg Atorvastatin Tab 10 mg 4,827,918 $648,389 $0.1343 * 102,957,010 $1,750,269 $0.0170 C

+ C

A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $2,878,089 for the year ended 30 June 2009 A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $5,953,386 for the year ended 30 June 2009 A Special Authority for the Manufacturers Price currently exists. The total cost, accounting for patients with Special Authority, was $10,440,546 for the year ended 30 June 2009 This was recently listed on the Pharmaceutical Schedule. A Special Authority for the Manufacturers Price currently exists

Tab 20 mg

6,791,393

$1,329,076

$0.1957

+ C

Tab 40 mg

8,504,025

$2,307,142

$0.2713

+ C

Tab 80 mg

$0.5427

+ C

Clopidogrel Tab 75 mg Compound Electrolytes Powder for soln for oral use 791,686 $226,422 $0.2860 C 1,820,845 $2,276,056 $1.2500 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Dextrose with Electrolytes Soln with electrolytes 90,789,984 $604,661 $0.0067 C

Sole supply would only be awarded to a range of flavours

Units

Cost

Unit Subsidy

DV Limit

Comments

Gemfibrozil Tab 300 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered Not currently listed on the Pharmaceutical Schedule. Capsule form would be considered

Tab 600 mg

C H

Sodium Chloride Inj 0.9%, 5 ml Inj 0.9%, 10 ml Inj 0.9%, 20 ml Inj 23.4%, 20 ml Sodium Fluorescein Inj 100 mg per ml H 1% 133,175 543,388 102,212 3,735 $30,630 $124,979 $40,169 $19,796 $0.2300 $0.2300 $0.3930 $5.3000 C H C H C H C H 1% 1% 1% 1%

Cardiovascular System

Acebutolol Cap 100 mg Cap 200 mg Tab 400 mg 60,820 130,884 $5,778 $20,863 $0.0950 $0.1594 C H C H C H 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Amiodarone Hydrochloride Inj 50 mg per ml, 3 ml Bisoprolol fumarate Tab 2.5 mg C

Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority Not currently listed on the Pharmaceutical Schedule. Tender Agreement may be subject to a Special Authority

4,793

$29,161

$6.0840

C H

Tab 5 mg

Tab 10 mg

Bumetanide Tab 1 mg Captopril Oral liq 5 mg per ml Tab 12.5 mg Tab 25 mg 85,273 505,495 830,687 $45,814 $10,514 $22,262 $0.5373 $0.0208 $0.0268 C H C H C H 1% 1% 1% 10 836,929 $136,922 $0.1636 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Captopril Tab 50 mg Cilazapril Tab 0.5 mg Tab 2.5 mg Tab 5 mg Cilazapril with Hydrochlorothiazide Tab 5 mg with Hydrochlorothiazide 12.5 mg Dobutamine Inj 12.5 mg per ml, 20 ml Doxazosin Mesylate Tab 2 mg Tab 4 mg Furosemide Inj 10 mg per ml, 2 ml Inj 20 mg per ml, 2 ml 19,591 $11,559 $0.5900 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

637,696

$24,232

$0.0380

C H

14,646,190 17,316,642 16,520,567

$1,074,054 $2,534,002 $3,546,415

$0.0733 $0.1463 $0.2147

C C C

17,897,458

$4,026,928

$0.2250

9,601,118 8,384,024

$438,771 $507,401

$0.0457 $0.0605

C H C H

1% 1%

Glyceryl Trinitrate Inj 5 mg per ml, 1 ml Inj 5 mg per ml, 10 ml Hydralazine Inj 20 mg per ml, 1 ml Prazosin Hydrochloride Tab 1 mg Tab 2 mg Tab 5 mg Spironolactone Tab 25 mg Tab 100 mg Terazosin Hydrochloride Tab 1 mg Tab 2 mg Tab 5 mg 3,816,567 2,895,729 $177,852 $167,952 $0.0893 $0.0466 $0.0580 C C C

This was recently listed on the Pharmceutical Schedule

H H

1% 1%

$269

$5.1800

C H

401,233 407,528 267,577

$22,188 $28,527 $31,307

$0.0553 $0.0700 $0.1170

C H C H C H

1% 1% 1%

5,328,826 1,295,640

$452,950 $281,154

$0.0850 $0.2170

C H C H

1% 1%

Dermatologicals

Calcipotriol Crm 50 mcg per g (pack size 30 g or less) 1,419,618 $821,817 $0.5789 C H 1%

Volume is aggregated for all pack sizes of calcipotriol cream

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Calcipotriol Crm 50 mcg per g (pack size greater than 30 g) 1,419,618 $821,817 $0.5789 C H 1%

Volume is aggregated for all pack sizes of calcipotriol cream Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol solution Volume is aggregated for all pack sizes of calcipotriol solution

Units

Cost

Unit Subsidy

DV Limit

Comments

Oint 50 mcg per g (pack size 30 g or less)

1,507,289

$1,043,044

$0.6920

C H

Oint 50 mcg per g (pack size greater than 30 g)

1,507,289

$1,043,044

$0.6920

C H

Soln 50 mcg per ml (pack size 30 ml or less)

313,503

$217,153

$0.6927

C H

Soln 50 mcg per ml (pack size greater than 30 ml)

313,503

$217,153

$0.6927

C H

Cetomacrogol Crm BP Coal Tar Soln BP $0.0730 C

There are two different subsidies, unit subsidy reflects the subsidy of the fully funded product. Market information unavailable

12,146,581

$85,026

$0.0070

Fusidic Acid Crm 2 % Oint 2 % Hydrocortisone Butyrate Scalp lotn 0.1% Hydrocortisone with Natamycin and Neomycin Crm 1% with natamycin 1% and neomycin sulphate 0.5% Oint 1% with natamycin 1% and neomycin sulphate 0.5% Magnesium Sulphate Paste (pack size 100 g or less) Malathion Liq 0.5% Shampoo 1% Menthol Crystals $0.2960 C

Market information unavailable

1,466,886 1,002,501

$386,280 $263,992

$0.2633 $0.2633

C H C H

1% 1%

3,642,476

$273,914

$0.0752

C H

1,793,319 817,977

$526,040 $239,940

$0.2933 $0.2933

C C

245,281

$9,137

$0.0373

C H

9,322,516 564,454

$232,597 $53,247

$0.0250 $0.0943

C C

Salicylic Acid Powder $0.0755 C

Market information unavailable

Sulphur Precipitated $0.0650 C

Market information unavailable

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Wool Fat with Mineral Oil Lotn hydrous 3% with mineral oil Zinc Crm BP 220,121 $2,884 $0.0131 * C 10,719,597 $60,030 $0.0056 * C Units Cost Unit Subsidy DV Limit Comments

Extemporaneously Compounded Preparations & Galenicals

Glycerol Liq BP $0.0124 C H 1%

Market information unavailable

Methyl Hydroxybenzoate Powder $0.4000 C

Market information unavailable

Methylcellulose Powder $0.1400 C

Market information unavailable

Propylene Glycol Liq $0.0354 C

Market information unavailable

Sodium Bicarbonate Powder BP $0.0196 C H 1%

Market information unavailable

Genito-Urinary System

Clotrimazole Pessaries 100 mg with applicator(s) Pessaries 500 mg with applicator Vaginal crm 1% with applicators Vaginal crm 2% with applicators Ergometrine Maleate Inj 500 mcg per ml, 1 ml Levonorgestrel Tab 30 mcg Tab 750 mcg - 1.5 mg 836,896 56,343 $65,955 $704,288 $0.0788 $12.5000 C C

Bids would be accepted for a tablet within this strength range

C C 1,914,684 1,086,351 $79,323 $149,373 $0.0414 $0.1375 C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

1,023

$2,373

$2.3200

C H

Oxybutynin Oral liq 5 mg per 5 ml Tab 5 mg Sodium Citro-Tartrate Grans effervescent 4 g sachets 1,372,285 $134,778 $0.0982 C 612,575 5,876,883 $65,272 $526,451 $0.1066 $0.0896 C H C H 1% 1%

Hormone Preparations - Systemic Excluding Contraceptive Hormones

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Hydrocortisone Inj 50 mg per ml, 2 ml Medroxyprogesterone Acetate Tab 2.5 mg Tab 5 mg Tab 10 mg Tab 100 mg Tab 200 mg Testosterone Transdermal patch 2.5 mg per day 105,858 $141,140 $1.3333 C H 1% 221,643 519,805 864,393 44,252 1,192 $15,293 $71,473 $218,115 $46,137 $3,102 $0.0690 $0.1375 $0.2523 $1.0426 $2.6020 C H C H C H C H C H 1% 1% 1% 1% 1% 6,999 $26,036 $3.7200 C H 1% 31,713 76,573 $136,366 $474,753 $4.3000 $6.2000 C H C H 1% 1% Units Cost Unit Subsidy DV Limit Comments

Infections - Agents for Systemic Use

Abacavir Sulphate Oral liq 20 mg per ml Tab 300 mg Abacavir sulphate with lamivudine Tab 600 mg with lamivudine 300 mg Abacavir Sulphate with Lamivudine and Zidovudine Tab 300 mg with lamivudine 150 mg, and zidovudine 300 mg Amoxycillin Cap 250 mg Cap 500 mg Cefaclor Monohydrate Cap 250 mg Grans for oral liq 125 mg per 5 ml Ciprofloxacin Inj 2 mg per ml, 100 ml Clarithromycin Tab 250 mg Clindamycin Inj phosphate 150 mg per ml, 4 ml Colistin Sulphomethate Inj 150 mg Emtricitabine Cap 200 mg 124,667 $1,276,590 $10.2400 C H 1% 7,452 $484,380 $65.0000 C H 1% 1,141 $22,192 $19.4500 C H 1% 86,986 $48,153 $0.5536 C H 1% H 1% 3,894,014 10,276,124 $1,125,370 $402,824 $0.2890 $0.0392 C H C H 1% 1% 1,728,107 10,097,812 $59,793 $550,331 $0.0346 $0.0545 C H C H 1% 1% C

Not currently listed on the Pharmaceutical Schedule

42,936 35,393

$17,890 $270,167

$0.4167 $7.6333

C H C H

1% 1%

60,587

$1,272,327

$21.0000

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Gentamicin Sulphate Inj 10 mg per ml, 1 ml $1.7120 C H 1%

Market information unavailable

Units

Cost

Unit Subsidy

DV Limit

Comments

Isoniazid Tab 100 mg Itraconazole Cap 100 mg Lamivudine Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 100 mg Tab 150 mg Lopinavir with ritonavir Oral liq 80 mg with ritonavir 20 mg per ml 17,838 $43,703 $2.4500 6,220 36,198 327,610 32,249 $2,333 $15,083 $1,673,151 $165,115 $0.3750 $0.4167 $5.1071 $5.1200 C C C C 581,374 $918,571 $1.5800 C H 1% 271,862 $55,732 $0.2050 C

+ C H + C H

Tender agreement may be subject to a Special Authority restriction Tender agreement may be subject to a Special Authority restriction

Tab 200 mg with ritonavir 50 mg

217,934

$1,334,846

$6.1250

Metronidazole Tab 200 mg Tab 400 mg Nystatin Cap 500,000 u Tab 500,000 u Phenoxymethylpenicillin (Penicillin V) Cap 250 mg Cap 500 mg Grans for oral liq benzathine 125 mg per 5 ml Grans for oral liq benzathine 250 mg per 5 ml Piperacillin Sodium with Tazobactam Sodium Inj 4 g with tazobactam sodium 500 mg Rifabutin Cap 150 mg Zidovudine (AZT) Cap 100 mg Oral liq 10 mg per ml 47,957 60,246 $139,075 $17,471 $2.9000 $0.2900 10,269 $72,975 $7.1063 C H 1% H 1% 555,005 2,342,365 2,061,408 4,896,391 $47,619 $381,805 $34,632 $89,114 $0.0858 $0.1630 $0.0168 $0.0182 C H C H C H C H 1% 1% 1% 1% 230,477 76,029 $53,655 $14,598 $0.2328 $0.1920 C H C H 1% 1% 288,833 1,103,006 $27,439 $193,026 $0.0950 $0.1750 C C

+ C H + C H

1% 1%

Musculoskeletal System

Colchicine Tab 500 mcg - 600 mcg 3,618,128 $347,340 $0.0960 C H 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Ibuprofen Oral liq 100 mg per 5 ml Indomethacin Cap 25 mg Cap 50 mg Cap long-acting 75 mg Suppos 100 mg Naproxen Tab long-acting 750 mg Tab long-acting 1,000 mg Naproxen Sodium Tab 275 mg Tab 550 mg Neostigmine Inj 2.5 mg per ml, 1 ml Orphenadrine Citrate Tab 100 mg Piroxicam Tab dispersible 10 mg Tab dispersible 20 mg Risedronate sodium Tab 5 mg C H 1%

Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currenty listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

27,842,543

$485,852

$0.0175

C H

291,147 782,475 589,424 39,921

$17,178 $54,382 $78,393 $19,295

$0.0590 $0.0695 $0.1330 $0.4833

C H C H C H C H

1% 1% 1% 1%

893,953 813,534

$178,791 $189,825

$0.2000 $0.2333

C H C H

1% 1%

1,890,518 4,289,670

$94,526 $549,078

$0.0500 $0.1280

C H C H

1% 1%

27,169

$11,031

$0.4060

C H

1,436,969

$266,414

$0.1854

C H

41,511 389,484

$2,698 $21,422

$0.0650 $0.0550

C H C H

1% 1%

Tab 30 mg

C H

Tab 35 mg

C H

Tab 150 mg

C H

Tenoxicam Tab 20 mg 1,763,099 $418,736 $0.2375 C H 1%

Nervous System

Alprazolam Tab 250 mcg Tab 500 mcg 327,241 282,290 $21,271 $24,277 $0.0650 $0.0860 C C 16

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Alprazolam Tab 1 mg Apomorphine Hydrochloride Inj 10 mg per ml Aspirin Tab dispersible or soluble 300 mg Bupivacaine Hydrochloride Inf 0.125%, 100 ml theatre pack Inf 0.125%, 200 ml theatre pack Inf 0.25%, 100 ml theatre pack Inj 0.5%, 8% glucose, 4 ml Caffeine Citrate Inj 10 mg per ml, 2.5 ml Oral liq 10 mg per ml Codeine Phosphate Tab 15 mg Tab 30 mg Tab 60 mg Dexamphetamine Sulphate Tab 5 mg Domperidone Tab 10 mg 6,579,837 $256,614 $0.0390 C

A Special Authority for full subsidy currently exists. The Special Authority would be removed should a tender be awarded

Units

Cost

Unit Subsidy

DV Limit

Comments

84,739

$13,304

$0.1570

2,157

$21,756

$10.0860

C H

3,077,961

$66,176

$0.0215

H H H 503 $2,465 $4.9000 C H

1% 1% 1% 1%

H H

1% 1%

4,033,866 18,209,124 1,785,587

$221,863 $1,547,776 $330,334

$0.0550 $0.0850 $0.1850

C H C H C H

1% 1% 1%

636,761

$108,249

$0.1700

C H

Ephedrine Sulphate Inj 30 mg per ml, 1 ml Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg Escitalopram Tab 10 mg Tab 20 mg C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

423,371

$131,245

$0.3100

C H

Fluoxetine Hydrochloride Cap 20 mg Tab dispersible 20 mg, scored Haloperidol Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 mcg 39,565 65,301 1,232,826 $67,419 $11,793 $60,778 $1.7040 $0.1806 $0.0493 C H C H C H 1% 1% 1% 17 21,564,650 854,866 $1,051,876 $156,725 $0.0488 $0.1833 C H C H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Haloperidol Tab 1.5 mg Tab 5 mg Imipramine Hydrochloride Tab 10 mg Tab 25 mg Ketamine Hydrochloride Inj 10 mg per ml C H 1%

Not currently listed in the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

258,263 262,642

$19,241 $61,695

$0.0745 $0.2349

C H C H

1% 1%

496,156 1,579,879

$54,379 $278,059

$0.1096 $0.1760

C H C H

1% 1%

Inj 50 mg per ml

C H

Inj 100 mg per ml

C H

Levodopa with Benserazide Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Cap long-acting 100 mg with benserazide 25 mg Tab dispersible 50 mg with benserazide 12.5 mg Lignocaine Viscous solution 2% C H 1%

Not currently listed on the Pharmaceutical Schedule

1,036,487 1,186,884 176,281 567,392 477,398

$82,919 $148,361 $44,070 $96,457 $47,740

$0.0800 $0.1250 $0.2500 $0.1700 $0.1000

C H C H C H C H C H

1% 1% 1% 1% 1%

Lignocaine Hydrochloride Inj 0.5%, 5 ml Pump spray 10%, 50 ml CFC-free Inj 1%, 5 ml Inj 1%, 20 ml Lignocaine Hydrochloride with Adrenaline Inj 1% with 1:100,000 of adrenaline, 5 ml Inj 1% with 1:200,000 of adrenaline, 20 ml Inj 2% with 1:200,000 of adrenaline, 20 ml Lignocaine with Prilocaine Hydrochloride Crm 2.5% with prilocaine hydrochloride 2.5% 5 g Crm 2.5% with prilocaine hydrochloride 2.5% 30 g Lithium carbonate Tab long-acting 400 mg 1,228,213 $197,128 $0.1605 C 577 1,335 $4,731 $1,825 $8.2000 $1.3667 C H C H 1% 1% H H H 1% 1% 1% 37,078 1,783 $31,146 $8,380 $0.8400 $4.7000 C C 11,967 $10,555 $0.8820 C H H 1% 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Lorazepam Tab 1 mg Tab 2.5 mg Methadone Hydrochloride Inj 10 mg per ml, 1 ml Tab 5 mg Metoclopramide Hydrochloride Oral liq 5 mg per 5 ml $0.0000 C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

4,504,048 256,352

$113,142 $10,562

$0.0251 $0.0412

C H C H

1% 1%

35,728 1,975,773

$217,941 $414,912

$6.1000 $0.2100

C H C H

1% 1%

Morphine Sulphate Cap long-acting 10 mg Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Cap long-acting 200 mg Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg Tab long-acting 200 mg 2,852,145 1,052,319 408,428 304,539 39,285 25,813 11,355 728,273 356,403 175,275 244,268 $513,386 $277,812 $294,068 $239,063 $66,785 $26,691 $10,674 $131,089 $128,305 $126,198 $207,628 $0.1800 $0.2640 $0.7200 $0.7850 $1.7000 $1.0340 $0.9400 $0.1800 $0.3600 $0.7200 $0.8500 C H C H C H C H C H C H C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

Not currently listed on the Pharmaceutical Schedule

Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Naltrexone hydrochloride Tab 50 mg Olanzapine Oradispersible 5 mg Orodispersible 10 mg Tab 2.5 mg Tab 5 mg Tab 10 mg Ondansetron Tab 4 mg Tab 8 mg Tab disp 4 mg Tab disp 8 mg 30,087 112,932 15,985 6,477 $51,689 $191,363 $27,462 $13,233 $1.7180 $1.6945 $1.7180 $2.0430 C H C H C H C H 1% 1% 1% 1% 84,773 $508,638 $6.0000 C H 1% 26,690 2,560 $107,828 $34,493 $4.0400 $13.4740 C H C H 1% 1%

+ + + + +

H H H H H

5% 5% 5% 5% 5%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Oxycodone Hydrochloride Cap 5 mg Cap 10 mg Cap 20 mg Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 2 ml Oral liq 5 mg per 5 ml Tab controlled-release 5 mg Tab controlled-release 10 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 80 mg Paracetamol Suppos 125 mg Suppos 250 mg Suppos 500 mg Paraldehyde Inj 5 ml Paroxetine hydrochloride Tab 20 mg Pethidine Hydrochloride Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 1.5 ml Inj 50 mg per ml, 2 ml Tab 50 mg Tab 100 mg Phenobarbitone Tab 15 mg Tab 30 mg Pramipexole Hydrochloride Tab 0.125 mg C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

1,039,973 695,650 372,631 22,764 21,769 715,606 640,801 1,415,423 879,265 303,822 139,168

$147,156 $194,086 $182,030 $65,560 $125,389 $32,059 $240,621 $788,391 $832,224 $505,712 $403,796

$0.1415 $0.2790 $0.4885 $2.8800 $5.7600 $0.0448 $0.3755 $0.5570 $0.9465 $1.6645 $2.9015

+ C H + C H + C H

C H C H C H

1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%

+ C H + C H + C H + C H + C H

66,981 43,621 129,304

$25,084 $31,407 $53,015

$0.3745 $0.7200 $0.4100

C H C H C H

1% 1% 1%

219

$65,700

$300.0000

C H

13,646,015

$2,683,716

$0.1967

C H

23,247

$24,177

$1.0400 $0.8700

C H C H C H C C

1% 1% 1%

70,243 278,785 105,727

$77,267 $83,636 $42,291

$1.1000 $0.3000 $0.4000

84,843 781,463

$4,018 $38,432

$0.0474 $0.0492

C H C H

1% 1%

Tab 0.250 mg

C H

Tab 1 mg

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Pramipexole Hydrochloride Tab 1.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

Prilocaine Hydrochloride Inj, 0.5%, 50 ml Inj, 2%, 5 ml Rizatriptan benzoate Wafer 10 mg Ropinirole Hydrochloride Tab 0.25 mg Tab 1 mg Tab 2 mg Tab 5 mg Sertraline Tab 50 mg C H 1%

H H

1% 1%

130,467

$1,101,141

$8.4400

+ C H

308,433 710,596 375,380 75,658

$29,007 $341,086 $271,346 $81,062

$0.0940 $0.4800 $0.7229 $1.0714

C H C H C H C H

1% 1% 1% 1%

Tab 100 mg

C H

Suxamethonium Inj 50 mg per ml, 2 ml Tetrabenazine Tab 25 mg Tolcapone Tab 100 mg Venlafaxine Tab immediate-release 12.5 mg C H 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction

116,287

$252,301

$2.1696

C H

116,011

$149,364

$1.2875

C H

Tab immediate-release 25 mg

C H

Tab immediate-release 37.5 mg

C H

Tab immediate-release 50 mg

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Venlafaxine Tab immediate-release 75 mg C H 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

Tab immediate-release 100 mg

C H

Oncology Agents and Immunosuppressants

Amsacrine Inj 75 mg Arsenic trioxide Inj 10 mg Azathioprine Inj 50 mg Tab 50 mg Bacillus Calmette-Guérin (BCG) Vaccine Inj containing equal to or greater than 500 million CFU H PCT 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement would be for non-vaccine use and may be subject to a Special Authority restriction

H PCT 1%

30 3,637,906

$1,390 $909,477

$46.3300 $0.2500

C H C H

1% 1%

Bleomycin sulphate Inj 15,000 iu Busulphan Tab 2 mg Carmustine Inj 100 mg Chlorambucil Tab 2 mg Cisplatin Inj 10 mg Inj 50 mg Inj 100 mg Cladribine Inj 1 mg per ml, 10 ml Inj 2 mg per ml, 5 ml Cyclophosphamide Tab 50 mg Cyclosporin A Cap 25 mg 1,032,971 $1,756,051 $1.7000 C H 1% 22 88,044 $45,272 $0.5142 C H 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%

Not currently listed on the Pharmaceutical Schedule

7,423

$3,555

$0.4789

85,751

$76,661

$0.8940

C H

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Cyclosporin A Cap 50 mg Cap 100 mg Oral liq 100 mg per ml Cytarabine Inj 100 mg Inj 500 mg Inj 1 g Inj 2 g Dacarbazine Inj 50 mg Inj 200 mg Dactinomycin (actinomycin D) Inj 0.5 mg Daunorubicin Inj 20 mg Etoposide Cap 50 mg Cap 100 mg Etoposide Phosphate Inj 100 mg (of etoposide base) Exemestane Tab 25 mg Fluorouracil Sodium Inj 25 mg per ml, 100 ml Inj 50 mg per ml, 10 ml Inj 50 mg per ml, 20 ml Inj 50 mg per ml, 50 ml Inj 50 mg per ml, 100 ml Flutamide Tab 250 mg Gemcitabine Hydrochloride Inj 200 mg Inj 1 g Imatinib Mesylate Tab 100 mg 395,319 $15,812,760 $40.0000 H PCT 1% H PCT 1% 453,951 $179,311 $0.3950 C H 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% 134,667 $785,558 $5.8333 C H 1% H PCT 1% 7,910 554 $134,759 $18,876 $17.0365 $34.0730 C H C H 1% 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1% $16.0000 $19.0720 $42.6500 C H C H C H H 1% 1% 1% 1% 280,201 488,652 16,189 $948,985 $3,310,031 $122,188 $3.3868 $6.7738 $7.5476 C H C H C H 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments

+ C H

Tender agreement may be subject to a Special Authority restriction

Lomustine Cap 10 mg H PCT 1% 23

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Lomustine Cap 40 mg Melphalan Inj 50 mg Tab 2 mg Mercaptopurine Tab 50 mg Mesna Tab 400 mg Tab 600 mg Inj 100 mg per ml, 4 ml Inj 100 mg per ml, 10 ml Methotrexate Inj 25 mg per ml, 2 ml Inj 25 mg per ml, 20 ml Inj 10 mg per ml, 0.75 ml prefilled syringe 6,882 23 $63,452 $1,846 $9.2200 $80.2500 C H C H C H 1% 1% 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

H PCT 1% 14,585 $18,266 $1.2524 C H 1%

212,009

$399,086

$1.8824

C H

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

Inj 10 mg per ml, 1 ml prefilled syringe

C H

Inj 10 mg per ml, 1.5 ml prefilled syringe

C H

Inj 10 mg per ml, 2 ml prefilled syringe

C H

Inj 10 mg per ml, 2.5 ml prefilled syringe

C H

Mitomycin C Inj 2 mg Inj 10 mg Mitozantrone Inj 2 mg per ml, 5 ml Inj 2 mg per ml, 10 ml Octreotide (somatostatin analogue) LAR inj 10 mg LAR inj 20 mg 226 953 $400,585 $1,772.5000 $2,247,889 $2,358.7500 C H C H 1% 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Octreotide (somatostatin analogue) LAR inj 30 mg Pentostatin (deoxycoformycin) Inj 10 mg Procarbazine Hydrochloride Cap 50 mg Sirolimus Oral liq 1 mg per ml Tab 1 mg Tab 2 mg Tacrolimus Cap 0.5 mg Cap 1 mg Cap 5 mg Temozolomide Cap 5 mg Cap 20 mg Cap 100 mg Cap 250 mg Teniposide Inj 10 mg per ml, 5 ml Thalidomide Cap 50 mg Thioguanine Tab 40 mg Thiotepa Inj 15 mg Topotecan Inj 1 mg H PCT 1%

Units

Cost

Unit Subsidy

DV Limit

Comments

744

$2,195,730 $2,951.2500

C H

H PCT 1%

2,839 83,240 3,572

$23,081 $676,741 $58,081

$8.1300 $8.1300 $16.2600

C H C H C H

1% 1% 1%

135,044 1,069,733 64,144

$288,994 $4,578,457 $1,372,682

$2.1400 $4.2800 $21.4000

C H C H C H

1% 1% 1%

3,957 8,369 7,341 382

$39,570 $284,546 $1,233,288 $160,440

$10.0000 $34.0000 $168.0000 $420.0000

C H C H C H C H

1% 1% 1% 1%

H PCT 1%

6,434

$25,005

$3.8864

C H

H PCT 1%

Inj 4 mg

H PCT 1%

Tretinoin Cap 10 mg Vincristine Sulphate Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml H PCT 1% H PCT 1% 25 H PCT 1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED (DRAFT)

Chemical Name Line Item Zoledronic Acid Inj 4 mg Inj 5 mg H H 1% 1% Units Cost Unit Subsidy DV Limit Comments

Respiratory System and Allergies

Beclomethasone Dipropionate Metered aqueous nasal spray, 50 mcg per dose 12,722,366 $149,488 $581,553 $0.0118 $0.0123 C H C H 1% 1%

Metered aqueous nasal spray, 100 mcg per dose 47,280,695 Budesonide Metered aqueous nasal spray, 50 mcg per dose 5,268,675

$61,907 $395,473

$0.0118 $0.0131

C H C H

1% 1%

Metered aqueous nasal spray, 100 mcg per dose 30,304,478 Ipratropium Bromide Aqueous nasal spray, 0.03% Nebuliser soln, 250 mcg per 1 ml Nebuliser soln, 500 mcg per 2 ml Loratadine Oral liq 1 mg per ml Tab 10 mg Salbutamol Oral liq 2 mg per 5 ml 1,019,202 8,544,371 14,238,914 784,748 78,380 412,284

$331,164 $16,852 $108,225

$0.4220 $0.2150 $0.2625

C C H C H 1% 1%

$311,870 $509,753

$0.0365 $0.0358

C H C H

1% 1%

$15,288

$0.0150

C H

Sensory Organs

Paraffin Liquid with Soft White Paraffin Eye oint with soft white paraffin Sodium Cromoglycate Eye drops 2% 494,850 $195,466 $0.3950 C 101,341 $105,105 $1.0371 C

Various

Desferrioxamine Mesylate Inj 500 mg Naloxone Hydrochloride Inj 400 mcg per ml, 1 ml 11,165 $73,689 $6.6000 C H 1%

Min-I-Jet would not be DV Pharmaceutical

22,093

$218,721

$9.9000

C H

Metadata

Title

Medical Groups/Interested Parties: Multi-product Tender consultation

Abstract

21 August 2009 2009/10 Multi-product Tender PHARMAC is seeking feedback from Medical Groups, DHB Hospital Pharmacies and other Interested Parties on: • • A proposal to tender certain pharmaceuticals for sole supply; and The draft process and terms and conditions…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.